Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
This former ASX tech darling is now 25% undervalued
Shares have fallen over 40% this year but revenue is still growing quickly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 6.90 | -0.07% |
| CAC 40 | 8,278.59 | 45.30 | 0.55% |
| DAX 40 | 26,347.45 | 80.26 | 0.31% |
| Dow JONES (US) | 52,231.89 | 157.86 | -0.30% |
| FTSE 100 | 10,751.59 | 31.28 | -0.29% |
| HKSE | 24,389.38 | 167.66 | -0.68% |
| NASDAQ | 25,065.87 | 187.27 | -0.74% |
| Nikkei 225 | 61,139.91 | 680.33 | 1.13% |
| NZX 50 Index | 14,149.51 | 17.90 | -0.13% |
| S&P 500 | 7,520.93 | 29.01 | -0.38% |
| S&P/ASX 200 | 9,122.70 | 6.30 | -0.07% |
| SSE Composite Index | 3,671.20 | 7.48 | 0.20% |